XTalks

JANUARY 26, 2024

Technological advancements are revolutionizing cancer research and therapies. This technology, which allows for precise editing of DNA at specific locations, has been a major focus in the field due to its potential to directly target and modify cancer-causing genes.

Research 118

Research Gene Editing Gene Genetics 118

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” . PLYMOUTH MEETING, Pa. , PLYMOUTH MEETING, Pa. , mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

Drug Discovery World

APRIL 8, 2024

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

pharmaphorum

APRIL 7, 2021

The collaboration will focus on combining Artios’ DNA damage response (DDR) drug candidates with Novartis’ radioligand therapies, which consist of tumour-targeting molecules carrying radioactive isotopes that can deliver a cell-killing dose of radiation to malignant cells. It’s also providing research funding.

DNA 52

DNA Licensing Licensing Gene Therapy 52

Drug Discovery World

APRIL 14, 2023

The American Association for Cancer Research (AACR) will honour the following cancer researchers, physician-scientists, advocates, and journalists during its annual meeting to be held April 14-19 at the Orange County Convention Center in Orlando, Florida. June’s award lecture will be held on Sunday April 16 at 4:30pm ET.

Genetics 52

Genetics Research Medicine Clinical Research 52

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA). These tumor-derived entities are used to derive genomic and proteomic data.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

JUNE 28, 2021

Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine. It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks. Compared to beta radiation, alpha radiation has a higher potency and shorter range.

Licensing 52

Licensing Licensing Medicine Development 52